The DOI matches its Crossref record.
TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN-12 IN PANCREATIC β-CELL
Abstract
FK506 (tacrolimus) is a strong immunosuppressant: it has been approved as a drug for liver transplantation in Japan, the United States, and the United Kingdom. One of its main adverse effects is hyperglycemia. Thus, in this study, we investigated the mechanism and the reversibility of the hyperglycemia caused by FK506. FK506 did not affect the glucose uptake by insulin into rat strio-muscle cell line, but suppressed insulin production in rat insulinoma cells. Two-week oral administration of FK506 at 10 mg/kg/day suppressed insulin production time-dependently at the transcriptional step in pancreatic beta-cells, while glucagon content in pancreatic alpha-cells was not affected. When FK506 administration was stopped in these rats, insulin mRNA transcription and insulin production returned to normal. This recovery indicates that the adverse effect of FK506 on the pancreas is reversible. A high content of FK506 binding protein-12 (FKBP-12) in the pancreatic beta-cells was confirmed by immunostaining with anti-human FKBP-12 mAb, but the content was less in the pancreatic alpha-cells and almost negligible in the acinar cells. In contrast, a high content of calcineurin in the pancreatic alpha-cells was confirmed by using anti-calcineurin polyclonal antibody, but this content was less in the pancreatic beta-cells and not found in the acinar cells. Thus, as in the case with NF-AT in T cells, these findings point to the reduction of unidentified nuclear factors for insulin mRNA transcription caused by the binding of FK506 to FKBP-12 and a subsequent inhibition of calcineurin in the beta-cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Calcineurin: Form and Function
Rusnak, F., & Mertz, P. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1483 · Cited by 1,373
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506
Drachenberg, C. B., Klassen, D. K., Weir, M. R., Wiland, A., Fink, J. C., Bartlett, S. T., Cangro, C. B., Blahut, S., & Papadimitriou, J. C. (1999) · Transplantation · doi:10.1097/00007890-199908150-00012 · Cited by 343
Spencer, C. M., Goa, K. L., & Gillis, J. C. (1997) · Drugs · doi:10.2165/00003495-199754060-00009 · Cited by 307
Risk for posttransplant diabetes mellitus with current immunosuppressive medications
Weir, M. R., & Fink, J. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70101-0 · Cited by 289
Metadata
- Authors
- TAMUKA, K., FUJIMURA, T., TSUTSUMI, T., NAKAMURA, K., OGAWA, T., ATLIMARU, C., HIRANO, Y., OHARA, K., OHTSUKA, K., SHIMOMURA, K., & KOBAYASHI, M.
- Venue
- Transplantation
- Published
- 1995-06
- Volume
- 59
- Issue
- 11
- Pages
- 1606-1612
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1989141061
- Cited by
- 175
- References
- 0
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN-12 IN PANCREATIC β-CELL. https://app.cochat.ai/papers/10.1097/00007890-199506000-00018
- The paper
- TAMUKA, K., FUJIMURA, T., TSUTSUMI, T., NAKAMURA, K., OGAWA, T., ATLIMARU, C., HIRANO, Y., OHARA, K., OHTSUKA, K., SHIMOMURA, K., & KOBAYASHI, M. (1995). TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN-12 IN PANCREATIC β-CELL. Transplantation. https://doi.org/10.1097/00007890-199506000-00018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.